In vaccinated individuals with mild-to-moderate COVID-19, VV116 was associated with faster symptom resolution.
VV116 (mindeudesivir) is an oral remdesivir analogue that blocks SARS-CoV-2 replication by targeting the viral RNA polymerase. In a previously reported phase 3 clinical trial in high-risk patients with COVID-19, VV116 was comparable to nirmatrelvir/ritonavir (Paxlovid) regarding time to clinical recovery (NEJM JW Infect Dis Jan 19 2023 and N Engl J Med 2023; 388:406). Now, investigators in China report results of a placebo-controlled trial in 1347 patients with mild-to-moderate COVID-19 during the Omicron era.
Participants were randomized 1:1 to receive 5 days of VV116 or placebo; about 44% had a risk factor for severe COVID-19. Median age was 35 (only 7% were aged ≥60). Almost all participants (97%) had received COVID-19 vaccination. Median…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)